The British pharma giant, GlaxoSmithKline’s new manufacturing plant in Karnataka (India)is almost complete and it will be able to produce around1 billion capsulesand 8 billion pillsper year for the emerging pharmacy market of India.
GlaxoSmithKline has invested USD 155 million means approximately 1000 crore in Karnataka for the new facility and warehouse. This new facility is situated at Vemgal,near Bengaluru.It was anticipated to open this year only but according to latest annual report ofGlaxoSmithKline India, now it is intended to be operational in next year.
The new plant is being established following to the expected expansion and development in gross sales for anti-inflammatoryand gastroenterologydrugs.This new facility is intended to provide work foraround 300 people.
GlaxoSmithKline is also investingapproximately USD 75 million on upgradationof its existing facility situated in Nasik to amplify its dermatology and thyroid contributions. That development includes establishment of a new plant for production of thyroid’s therapeutics Eltroxin. For this Eltroxin producing plant about USD17.8 million is being invested. The new Eltroxinplant will be functional by 2018. The upgradation also includes investing in infrastructure over all areas with particularlyconcentrating on good manufacturing practices (GMP), sustainability and safety.
WhileEx-CEO of GlaxoSmithKline, Andrew Witty declared the new Bangalore plant, he said that amid the technologies used in the new plant, it would be uninterruptedmanufacturing, a technology that goes away from group production, calling for smaller plants with lesser operating cost.
GlaxoSmithKline has been number one in exploring sustainable production techniques and the facilitiessees LEED construction standards, including reprocessed waste water and integrating solar powered lighting.
Some reports revealed that, GlaxoSmithKline is also searching for gender diversity in the employeesit is hiring for the new facility and until now, around 30 percent of new workforces are women, including 4 in leadership characters.
GlaxoSmithKline India endeavors to gain beneficial bulk growth in a competitory and partially cost-controlled generic drug market by concentrating on rendering quality yield. It is also amplifying its technicalpotentials to improve efficiency of its healthcare and field force participation with medical professionals.
GlaxoSmithKline also welcomed the government's act of medical professionals prescribing inexpensive generic drugs.It furthermorepraised the government's attempts to guarantee the quality of generic medicinessanctioned by the country’s FDAs.